A composition for promoting transdermal absorption and its application

A composition and transdermal technology, which can be used in drug combinations, inactive components of polymer compounds, skin diseases, etc., and can solve the problems of high-energy phosphate bonds easily broken and ATP instability.

Active Publication Date: 2021-04-20
FUJIAN LONGSHENG BIOLOGICAL TECH CO LTD
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] But ATP is unstable, its last high-energy phosphate bond is easy to break, and at the same time releases a lot of energy. The reaction formula is ADP hydrolysis to generate ADP+Pi (free phosphate group)+energy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A composition for promoting transdermal absorption and its application
  • A composition for promoting transdermal absorption and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 The effect of the combination of Gp4g and TD-1, and the combination of ATP and TD-1 on the transdermal efficiency of EGF in the abdominal skin tissue of rats.

[0038] TD-1 is a short peptide of ACSSSPSKHCG; EGF is a recombinant human epidermal growth factor (ATP helps TD-1 mediate the fusion transdermal protein drug transdermal in this application, taking human epidermal growth factor TD-1-huEGF as an example, the following text huEGF is represented by EGF)

[0039] Gp4g (diguanosine tetraphosphate) was purchased from Tianjin Qiangweite Biotechnology Co., Ltd. (product number E0012), INCI name: ARTEMIA EXTRACT. Adenosine triphosphate (ATP) was purchased from Bio Basic Inc., Canada (Product No. AB0020). Recombinant human epidermal growth factor (EGF) was purchased from Shenzhen Huashengyuan Gene Engineering Development Co., Ltd.

[0040] After abdominal depilation of SD rats (Shanghai Slack Experimental Animal Co., Ltd., all rats are from this source), intac...

Embodiment 2

[0051] Example 2 Comparison of TD-1-EGF and TD-1-EGF+ATP Transdermal Drugs

[0052] TD-1-EGF comes from Fujian Longsheng Biotechnology Co., Ltd., product number LS-102. The recombinant plasmid was constructed by Fujian Longsheng Biotechnology Co., Ltd., and the target protein was expressed and purified using the E. coli prokaryotic expression system.

[0053] TD-1-EGF is a proven transdermal fusion protein drug (Ruan R Q, Wang S S, WangCL, et al. Transdermal delivery of human epidermal growth factor facilitated by a peptide chaperon.[J]. European Journal of Medicinal Chemistry, 2013, 62(62C):405-409.), in this example, during the transdermal administration of TD-1-mediated transdermal fusion protein drug TD-1-EGF, exogenously supplement ATP to skin cells A precursor, Gp4g (diguanosine tetraphosphate), was synthesized to study the effect of Gp4g on the transdermal efficiency of the transdermal fusion protein drug TD-1-EGF.

[0054] After abdominal depilation of SD rats (Shang...

Embodiment 3

[0073] Example 3 A skin external preparation containing a transdermal administration composition, which includes the following components in mass percent:

[0074] TD-1-EGF (transdermal EGF, specification 20ug / mL): 1%

[0075] Gp4g: 1%

[0076] Sodium hyaluronate: 0.05%

[0077] Aloe Vera Extract: 0.5%

[0078] Centella asiatica extract: 0.05%

[0079] Rosemary Leaf Extract: 0.05%

[0080] Glycyrrhiza glabra extract: 0.05%

[0081] VC polysaccharide: 0.5%

[0082] Butanediol: 4%

[0083] Hydroxyethylurea: 0.5%

[0084] Glyceryl polyethers-26: 2%

[0085]Preservatives (A631): 0.5%;

[0086] Flavor: 0.02%;

[0087] The above ingredients were dissolved in purified water.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a composition for promoting transdermal absorption and its application, and also provides an application of Gp4g (diguanosine tetraphosphate), and also provides a drug containing a transdermal composition, and a drug containing a transdermal Skin topical formulations for administering the composition. In the present invention, the exogenously added Gp4g can significantly promote the transdermal drug delivery ability mediated by the transdermal enhancer peptide (TD1).

Description

technical field [0001] The invention belongs to the field of drug delivery, and in particular relates to a composition for promoting transdermal absorption and its application. Background technique [0002] A short peptide TD-1 consisting of 11 amino acids that can efficiently enhance the transdermal absorption of protein drugs screened by the University of Science and Technology of China using phage display technology can help insulin at a therapeutic level pass through the skin of diabetic rats and enter the blood circulation , to achieve a good hypoglycemic effect, and at the same time, it can also assist the transdermal absorption of human growth hormone (Human Growth Hormone). These works were simultaneously published in the April 2006 issue of "Nature---Biotechnology", which has attracted the attention of international colleagues. The ability to efficiently enhance the transdermal absorption of protein drugs is obviously an advantage of the transdermal enhancing pepti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/42A61K47/26A61K38/18A61P17/00A61K8/64A61K8/60A61Q19/00A61Q19/02
CPCA61K8/606A61K8/64A61K38/1808A61K47/26A61K47/42A61Q19/00A61Q19/02
Inventor 魏鹏飞阮仁全温龙平翁雪荣饶照明
Owner FUJIAN LONGSHENG BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap